FDA Guidance Documents for HCT/P Regulation
The U.S. Food and Drug Administration publishes guidance documents to clarify regulatory expectations governing Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps). These documents help explain how the agency interprets provisions of 21 CFR Part 1271.
Guidance documents provide insight into how regulatory criteria such as minimal manipulation, homologous use, donor eligibility determination, and manufacturing safeguards may be evaluated in regulatory contexts.
Minimal Manipulation Guidance
FDA Guidance for Industry: Minimal Manipulation of Human Cells, Tissues, and Cellular and Tissue-Based Products
This document explains how the FDA interprets minimal manipulation under 21 CFR 1271.3(f), including distinctions between structural tissue and cellular or nonstructural tissue processing.
See also: Minimal Manipulation Overview
Homologous Use Guidance
FDA Guidance for Industry: Homologous Use of Human Cells, Tissues, and Cellular and Tissue-Based Products
This guidance explains how intended use statements may influence regulatory classification under 21 CFR 1271.10(a).
See also: Homologous Use Interpretation
Donor Eligibility Guidance
FDA Guidance for Industry: Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products
This guidance explains screening and testing procedures designed to reduce communicable disease transmission risks associated with human cell and tissue products.
See also: Donor Eligibility Requirements
Current Good Tissue Practice Guidance
FDA Guidance for Industry: Current Good Tissue Practice (cGTP)
This guidance addresses manufacturing safeguards including processing, labeling, storage, and distribution requirements for HCT/P products regulated under 21 CFR Part 1271 Subpart D.
See also: Current Good Tissue Practice Overview
Relationship Between FDA Guidance and Regulations
FDA guidance documents do not create legally enforceable requirements. Instead, they describe the agency's current thinking regarding regulatory interpretation and compliance expectations.
Healthcare organizations and tissue establishments frequently review these materials when evaluating regulatory frameworks associated with HCT/P products.
Related Regulatory Education Pages
- 21 CFR Part 1271 Regulatory Framework
- Section 361 vs Section 351 Classification
- Tissue Chain of Custody Documentation
- HCT/P Establishment Registration
- FDA Enforcement Overview
- Regulatory Resource Library
This information is provided for educational purposes only.
Certain referenced materials may be regulated as Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) under 21 CFR Part 1271. Registration under 21 CFR Part 1271 does not constitute FDA approval, clearance, endorsement, or evaluation of safety or effectiveness.
This information is not intended to diagnose, treat, cure, or prevent any disease.